|Bid||48.19 x 900|
|Ask||60.65 x 1100|
|Day's Range||48.19 - 50.09|
|52 Week Range||30.38 - 63.21|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2020 - Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.83|
Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September 30th. In this article, we look at what those funds think of Regenxbio Inc (NASDAQ:RGNX) based on that data. […]
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced interim data from the first cohort of the ongoing Phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome. RGX-121 is an investigational one-time gene therapy designed to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme direct to the central nervous system (CNS) using the AAV9 vector.
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of REGENXBIO Inc. (NASDAQ: RGNX).
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.
Regenxbio stock toppled below its 50-day moving average early Wednesday after the U.S. Food and Drug Administration put one of the biotech company's gene therapy candidates on hold.
Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md. , Nov. 5, 2019 /PRNewswire/ -- Initiation of RGX-314 Phase IIb trial for wet AMD and IND filing for Phase II trial in diabetic retinopathy now expected in Q1 2020 as a result of partial ...
Bioverativ formed a perfect double bottom, a key chart pattern for growth stock hunters, and broke out ahead of its big 61% gain on news it's being bought by Sanofi.
“Our recent partnerships with REGENXBIO, Bausch Health, and Aura Biosciences demonstrate the broad applicability of our suprachoroidal space injection platform to potentially treat multiple ocular diseases including wet AMD, uveitic macular edema, and choroidal melanoma. With these collaborations and planned internal research and development efforts, we look forward to continuing to expand our pipeline,” said George Lasezkay, Pharm.D., J.D., Chief Executive Officer of Clearside. “Results from multiple preclinical studies support the potential safety and effectiveness of suprachoroidally administered AAV-based gene therapy, and we are excited to advance our partnership with REGENXBIO,” said Thomas A. Ciulla, M.D., MBA, Chief Medical Officer of Clearside.
ROCKVILLE, Md. , Oct. 29, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
REGENXBIO Inc. (NASDAQ:RGNX) shareholders might be concerned after seeing the share price drop 23% in the last...
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
ROCKVILLE, Md. , Oct. 17, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
The prospect of RegenxBio’s product could change the game for the roughly 2 million people who suffer from wet age-related macular degeneration in the U.S., Europe and Japan.
ROCKVILLE, Md., Oct. 11, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced interim data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). The results were presented by Jeffrey S. Heier, M.D., Co-President and Director of Retina Research at Ophthalmic Consultants of Boston and primary investigator for the trial, in a podium presentation at the Retina Subspecialty Day program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA.
Notwithstanding the ESMO conference generating some huge moves in some stocks, last week turned out to be a muted one for biotechs. A few FDA approvals came through, with Puma Biotechnology Inc (NASDAQ: ...
Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.